➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
Harvard Business School
Medtronic
McKesson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209863


Email this page to a colleague

« Back to Dashboard

NDA 209863 describes XYOSTED (AUTOINJECTOR), which is a drug marketed by Antares Pharma Inc and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug. Additional details are available on the XYOSTED (AUTOINJECTOR) profile page.

The generic ingredient in XYOSTED (AUTOINJECTOR) is testosterone enanthate. There are sixty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the testosterone enanthate profile page.
Summary for 209863
Tradename:XYOSTED (AUTOINJECTOR)
Applicant:Antares Pharma Inc
Ingredient:testosterone enanthate
Patents:16
Formulation / Manufacturing:see details
Pharmacology for NDA: 209863
Mechanism of ActionAndrogen Receptor Agonists
Suppliers and Packaging for NDA: 209863
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863 NDA Antares Pharma, Inc. 54436-200 54436-200-01 1 SYRINGE in 1 CARTON (54436-200-01) > .5 mL in 1 SYRINGE (54436-200-03)
XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863 NDA Antares Pharma, Inc. 54436-200 54436-200-04 4 SYRINGE in 1 CARTON (54436-200-04) > .5 mL in 1 SYRINGE (54436-200-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength50MG/0.5ML (50MG/0.5ML)
Approval Date:Sep 28, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 28, 2021
Regulatory Exclusivity Use:NEW PRODUCT
Patent:⤷  Try it FreePatent Expiration:Feb 19, 2035Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
Patent:⤷  Try it FreePatent Expiration:Jul 31, 2031Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 209863

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-001 Sep 28, 2018 ⤷  Try it Free ⤷  Try it Free
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-002 Sep 28, 2018 ⤷  Try it Free ⤷  Try it Free
Antares Pharma Inc XYOSTED (AUTOINJECTOR) testosterone enanthate SOLUTION;SUBCUTANEOUS 209863-003 Sep 28, 2018 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Merck
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.